Collegium Pharmaceutical (COLL) Accumulated Expenses (2014 - 2026)

Collegium Pharmaceutical's Accumulated Expenses history runs 13 years deep, the most recent figure standing at $58.1 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 1299.47% year-over-year to $58.1 million in Q1 2026; TTM through Mar 2026 was $58.1 million, a 1299.47% increase from a year earlier, with the FY2025 full-year figure at $62.5 million, down 13.39% from the prior year.
• Accumulated Expenses eased to $58.1 million in Q1 2026 per COLL's latest filing, from $62.5 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $72.1 million in Q4 2024 and bottomed at $467000.0 in Q3 2022.
• The 5-year median for Accumulated Expenses is $4.3 million (2024), against an average of $21.5 million.
• Biggest YoY gain for Accumulated Expenses was 4632.3% in 2022; the steepest drop was 97.73% in 2022.
• Year by year, Accumulated Expenses stood at $1.2 million in 2022, then soared by 136.18% to $2.9 million in 2023, then surged by 2428.01% to $72.1 million in 2024, then slipped by 13.39% to $62.5 million in 2025, then fell by 6.91% to $58.1 million in 2026.
• Per Business Quant, the three latest COLL Accumulated Expenses figures stand at $58.1 million (Q1 2026), $62.5 million (Q4 2025), and $5.2 million (Q3 2025).